{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:47:30Z","timestamp":1768337250183,"version":"3.49.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) is a frequent occurrence in patients with cancer. However, it is not known whether treatment with different classes of anticoagulants impacts the risk of subsequent arterial thromboembolism. We performed a retrospective, population-based cohort study using Surveillance, Epidemiology, and End Results data linked with Medicare claims. Patients were eligible for study inclusion if they had a diagnosis of primary brain, colorectal, gastric, pancreatic, lung, or ovarian cancer between 2007 and 2015, were diagnosed with VTE, and had a prescription claim for a direct oral anticoagulant (DOAC), low-molecular-weight heparin (LMWH), or warfarin. We matched patients by propensity score in a 1:1:1 ratio into anticoagulant treatment groups based on their baseline demographic information, cancer-specific characteristics, and cardiovascular comorbidities. The primary aim of the study was to determine and compare the 6-month cumulative incidence of ischemic stroke across anticoagulant classes. The study comprised 4875 total patients with 1625 in each treatment group. At 6 months, the cumulative incidence of ischemic stroke was 5.6% (95% confidence interval [CI], 5.0-6.3) overall and 6.8% (95% CI, 5.6-8.1) in the DOAC, 4.9% (95% CI, 3.9-6.0) in the LMWH, and 5.2% (95% CI, 4.1-6.2) in the warfarin treatment groups (P = .040). We identified hypertension (odds ratio [OR], 1.75), atrial fibrillation\/flutter (OR, 1.37), DOAC use (OR, 1.36), and previous stroke (OR, 3.59) as statistically significant risk factors for ischemic stroke in the multivariable modeling. In conclusion, ischemic stroke is a common occurrence after cancer-associated VTE and may occur more frequently in patients treated with DOACs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017523","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:02:28Z","timestamp":1755892948000},"page":"14-24","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-4339","authenticated-orcid":false,"given":"Sirui","family":"Ma","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Cheng","family":"Chang","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Danbury Hospital, Danbury, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-6161","authenticated-orcid":false,"given":"Cho-Han","family":"Chiang","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-6529","authenticated-orcid":false,"given":"Junmin","family":"Song","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-7228","authenticated-orcid":false,"given":"Yu-Che","family":"Lee","sequence":"additional","affiliation":[{"name":"5Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo, Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1041-4797","authenticated-orcid":false,"given":"Ko-Yun","family":"Chang","sequence":"additional","affiliation":[{"name":"6Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[{"name":"7Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-1751","authenticated-orcid":false,"given":"Thita","family":"Chiasakul","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Department of Medicine, Faculty of Medicine, Center of Excellence in Translational Hematology, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1705-6249","authenticated-orcid":false,"given":"Ellen P.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"7Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"9Frailty Research Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6893","authenticated-orcid":false,"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[{"name":"10Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"12Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-3398","authenticated-orcid":false,"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"additional","affiliation":[{"name":"10Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"12Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"2","key":"2026011309113727900_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"2026011309113727900_bib2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026011309113727900_bib3","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.rpth.2024.102393","article-title":"Cancer and arterial thrombosis: therapeutic options","volume":"8","author":"Cheong","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2026011309113727900_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaccao.2021.02.007","article-title":"Arterial thromboembolism in cancer patients: a Danish population-based cohort study","volume":"3","author":"Mulder","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"8","key":"2026011309113727900_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2026011309113727900_bib6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.mayocp.2020.05.045","article-title":"Incidence and risk of various types of arterial thromboembolism in patients with cancer","volume":"96","author":"Wang","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"2026011309113727900_bib7","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2026011309113727900_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026011309113727900_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/jth.15600","article-title":"Previously undiagnosed cancer in patients with arterial thrombotic events - a population-based cohort study","volume":"20","author":"Leader","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026011309113727900_bib10","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/01.WNL.0000129912.56486.2B","article-title":"Stroke in patients with cancer: incidence and etiology","volume":"62","author":"Cestari","year":"2004","journal-title":"Neurology"},{"issue":"17","key":"2026011309113727900_bib11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2026011309113727900_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2026011309113727900_bib13","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026011309113727900_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2023.05.017","article-title":"Arterial events in cancer patients treated with apixaban for venous thrombosis","volume":"228","author":"Larsen","year":"2023","journal-title":"Thromb Res"},{"issue":"4","key":"2026011309113727900_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.27239","article-title":"Cancer-associated non-bacterial thrombotic endocarditis-clinical series from a single institution","volume":"99","author":"Patrzalek","year":"2024","journal-title":"Am J Hematol"},{"issue":"24","key":"2026011309113727900_bib16","doi-asserted-by":"crossref","first-page":"e2477","DOI":"10.1212\/WNL.0000000000207341","article-title":"Clinical and demographic characteristics, mechanisms, and outcomes in patients with acute ischemic stroke and newly diagnosed or known active cancer","volume":"100","author":"Costamagna","year":"2023","journal-title":"Neurology"},{"issue":"24","key":"2026011309113727900_bib17","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"2026011309113727900_bib18","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020","edition":"1st ed"},{"issue":"21","key":"2026011309113727900_bib19","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.2024.7741","article-title":"Causal inference about the effects of interventions from observational studies in medical journals","volume":"331","author":"Dahabreh","year":"2024","journal-title":"JAMA"},{"issue":"55","key":"2026011309113727900_bib20","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"7","key":"2026011309113727900_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwr146","article-title":"Use of Surveillance, Epidemiology, and End Results-Medicare data to conduct case-control studies of cancer among the US elderly","volume":"174","author":"Engels","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"11","key":"2026011309113727900_bib22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/jth.15519","article-title":"Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026011309113727900_bib23","doi-asserted-by":"crossref","first-page":"e1004012","DOI":"10.1371\/journal.pmed.1004012","article-title":"Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: a population-based cohort study","volume":"19","author":"Khan","year":"2022","journal-title":"Plos Med"},{"issue":"7","key":"2026011309113727900_bib24","doi-asserted-by":"crossref","first-page":"e2325283","DOI":"10.1001\/jamanetworkopen.2023.25283","article-title":"Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis","volume":"6","author":"Riaz","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026011309113727900_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of rivaroxaban in anti phospholipid syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026011309113727900_bib26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026011309113727900_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","article-title":"Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States","volume":"126","author":"White","year":"2010","journal-title":"Thromb Res"},{"key":"2026011309113727900_bib28","unstructured":"National Cancer Institute\n          . Drugs approved for different types of cancer. Accessed 8 April 2024. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/cancer-type."},{"key":"2026011309113727900_bib29","unstructured":"Division of Cancer Control and Population Sciences NCI\n          . Cancer Medications Enquiry Database (CanMED). Version 1.7.3. 2020. Accessed 28 August 2025. https:\/\/seer.cancer.gov\/oncologytoolbox\/."},{"issue":"7","key":"2026011309113727900_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","article-title":"Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ elixhauser comorbidity index","volume":"55","author":"Moore","year":"2017","journal-title":"Med Care"},{"issue":"10","key":"2026011309113727900_bib31","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"2026011309113727900_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"issue":"2","key":"2026011309113727900_bib33","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"16","key":"2026011309113727900_bib34","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026011309113727900_bib35","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtha.2024.12.029","article-title":"Risk of ischemic stroke after cancer diagnosis: a population-based matched cohort study","volume":"23","author":"Siegal","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026011309113727900_bib36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.24325","article-title":"Association between incident cancer and subsequent stroke","volume":"77","author":"Navi","year":"2015","journal-title":"Ann Neurol"},{"issue":"9","key":"2026011309113727900_bib37","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am J Med"},{"issue":"7","key":"2026011309113727900_bib38","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1055\/s-0042-1757899","article-title":"Predictors of recurrent venous thromboembolism or arterial thrombotic events during and after anticoagulation for a first venous thromboembolism","volume":"49","author":"Noumegni","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"2026011309113727900_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2022.04.016","article-title":"Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: a prospective cohort study","volume":"214","author":"Noumegni","year":"2022","journal-title":"Thromb Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/14\/2478172\/blooda_adv-2025-017523-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/14\/2478172\/blooda_adv-2025-017523-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:11:47Z","timestamp":1768313507000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/14\/546867\/Comparison-of-anticoagulants-and-risk-of-ischemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017523","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,29]]}}}